A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms PSTELLAR
- Sponsors Janssen Biotech
- 09 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 21 Aug 2013 Planned end date changed from 1 Sep 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.